Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4441011 | 0.90 | SLC6A5 (0.55) | SLC6A5CHRM2CHRM1TMEM97SIGMAR1 | |
| SCHEMBL2388388 | 0.89 | SLC6A5 (0.57) | SLC6A5CHRM2CHRM1TMEM97SIGMAR1 | |
| SCHEMBL2390334 | 0.89 | UTS2R (0.63) | SLC6A5CHRM2CHRM1TMEM97SIGMAR1 | |
| SCHEMBL61628 | 0.84 | DRD4 (0.78) | SLC6A5TMEM97SIGMAR1SLC6A12MCHR1 | |
| SCHEMBL12437572 | 0.83 | TMEM97 (0.61) | SLC6A5TMEM97SIGMAR1SLC6A12MCHR1 | |
| SCHEMBL15171511 | 0.82 | PRKAA2 (0.59) | MCHR1DRD4KMT2AHTR2ACYP3A4 | |
| SCHEMBL14146933 | 0.82 | UTS2R (0.62) | SLC6A5SLC6A12MCHR1DRD4MEN1 | |
| SCHEMBL2393679 | 0.82 | DRD4 (0.69) | SLC6A5TMEM97SIGMAR1SLC6A12MCHR1 | |
| SCHEMBL2390910 | 0.82 | MAPK1 (0.65) | SLC6A5TMEM97SIGMAR1SLC6A12MCHR1 | |
| SCHEMBL61848 | 0.81 | TMEM97 (0.83) | TMEM97SIGMAR1SLC6A12MCHR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | claimed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | claimed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | claimed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2079694-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | SLC6A5 4736/4885CHRM2 868/4885CHRM1 1091/4885 |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | SLC6A5 4736/4885CHRM2 868/4885CHRM1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.